| Identification | Back Directory | [Name]
Acetic acid, 2-[3-[[3'-[[[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]amino]carbonyl]-5'-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4'-methyl[1,1'-biphenyl]-4-yl]oxy]propoxy]- | [CAS]
2750350-39-9 | [Synonyms]
Acetic acid, 2-[3-[[3'-[[[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]amino]carbonyl]-5'-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4'-methyl[1,1'-biphenyl]-4-yl]oxy]propoxy]- | [Molecular Formula]
C34H43N3O7 | [MOL File]
2750350-39-9.mol | [Molecular Weight]
605.72 |
| Chemical Properties | Back Directory | [Boiling point ]
831.0±65.0 °C(Predicted) | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO : ≥ 160 mg/mL (264.15 mM) | [form ]
Solid | [pka]
3.47±0.10(Predicted) | [color ]
Yellow to brown |
| Hazard Information | Back Directory | [Uses]
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) incorporates a ligand for EZH2, and a PROTAC linker, which recruit E3 ligases. Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) can be used for the research of lymphoma[1]. | [IC 50]
EZH2 | [storage]
4°C, away from moisture | [References]
[1] Tu Y, et al. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. J Med Chem. 2021 Jul 22;64(14):10167-10184. DOI:10.1021/acs.jmedchem.1c00460 |
|
|